8-K: 4D Molecular Therapeutics Reports Q1 2025 Financial Results, Highlights Progress in Wet AMD and DME Programs

4D Molecular Therapeutics announces Q1 2025 financial results, highlighting the initiation of Phase 3 clinical trials for 4D-150 in wet AMD and progress in other key programs.

Summary

• 4D Molecular Therapeutics (4DMT) reported its financial results for the first quarter of 2025.
• The company is focusing its pipeline on 4D-150 for wet AMD and DME, and 4D-710 for cystic fibrosis.
• The first patient has been enrolled in the 4FRONT-1 Phase 3 clinical trial for wet AMD, with over 50 clinical trial sites open.
• Initiation of the second 4D-150 Phase 3 clinical trial (4FRONT-2) is expected in Q3 2025, with topline data from both trials expected in H2 2027.
• The FDA granted RMAT designation for 4D-150 in DME, adding to previous designations for wet AMD.
• As of March 31, 2025, 4DMT had $458 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028.
• Research and development expenses for Q1 2025 were $40.7 million, compared to $27.9 million in Q1 2024.
• The net loss for Q1 2025 was $48.0 million, compared to a net loss of $32.4 million in Q1 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong cash position, progress in clinical trials, and regulatory designations. However, the increased net loss and paused investment in some programs temper the overall outlook.

Positives

• The company has a strong cash position of $458 million, expected to fund operations into 2028.
• 4D-150 continues to be well-tolerated in clinical trials.
• The FDA has aligned with the company on a registrational path for 4D-150 in DME, potentially requiring only a single Phase 3 clinical trial.
• RMAT designation from the FDA validates the potential of 4D-150 in treating DME.
• The company is focusing on core programs with high value.

Negatives

• The company paused additional capital allocation for several programs, pending additional financing or partnerships.
• Development of 4D-110 for choroideremia and 4D-125 for X-linked retinitis pigmentosa has been terminated.
• The net loss for Q1 2025 increased to $48.0 million from $32.4 million in Q1 2024.

Risks

• Clinical trial outcomes may not be favorable.
• Regulatory approvals are not guaranteed.
• The company may need to seek additional financing or partnerships to advance paused programs.
• The company explicitly disclaims any obligation to update any forward-looking statements.

Future Outlook

4DMT expects its current cash position to fund planned operations into 2028, including the completion of Phase 3 clinical trials for 4D-150 in wet AMD and ongoing development of 4D-150 in DME and 4D-710 in CF.

Management Comments

• David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT, stated that the first quarter of 2025 marked a pivotal moment for 4DMT as they focused their pipeline on their highest value programs, 4D-150 and 4D-710.
• He also mentioned that the company is well positioned to execute on its mission to dramatically improve lives and outcomes for patients living with retinal vascular diseases with 4D-150.
• He noted that the company's strong balance sheet provides an expected operational runway into 2028, enabling them to deliver topline results from both wet AMD Phase 3 clinical trials in H2 2027 without raising additional capital.

Industry Context

4DMT is operating in the competitive gene therapy space, focusing on ophthalmology and pulmonology. The progress of 4D-150 in wet AMD and DME, along with the RMAT designation, positions the company as a potential leader in these indications. The focus on core programs and extended cash runway suggests a strategic approach to navigating the challenges of drug development.

Comparison to Industry Standards

• The 83% and 94% reduction in injection burden with 4D-150 in wet AMD, compared to aflibercept, is a significant improvement over current standards of care, which typically require frequent injections.
• Companies like Regeneron (aflibercept/Eylea) and Roche/Genentech (Vabysmo) are key competitors in the wet AMD and DME markets.
• The single Phase 3 trial pathway agreed upon with the FDA for DME is a positive development, potentially accelerating the path to market compared to the traditional two-trial approach.
• The $458 million cash position provides a competitive advantage, allowing 4DMT to fund its clinical programs through key milestones.

Stakeholder Impact

• Shareholders: The extended cash runway and progress in clinical trials are positive for shareholders.
• Patients: The potential for reduced injection burden with 4D-150 could significantly improve the quality of life for patients with wet AMD and DME.
• Employees: The focus on core programs may lead to restructuring or reallocation of resources.

Next Steps

• Initiate the second 4D-150 Phase 3 clinical trial (4FRONT-2) in Q3 2025.
• Present 52-week interim data update from SPECTRA Part 1 Clinical Trial in Q3 2025.
• Share data and programmatic updates in H2 2025 for 4D-150 in wet AMD and DME, and 4D-710 in cystic fibrosis lung disease.
• Present interim data from AEROW clinical trial and program update in H2 2025.
• Report 2-year data from Phase 1/2a and 18-month data from Phase 2b cohorts in Q4 2025.
• Report topline data from both 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials in H2 2027.

Key Dates

Keywords

4DMT, 4D Molecular Therapeutics, Financial Results, Clinical Trials, Wet AMD, DME, 4D-150, 4D-710, RMAT Designation, Gene Therapy, Ophthalmology, Cystic Fibrosis